{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:31:44Z","timestamp":1746325904109},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin. J. Integr. Med."],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11655-019-3152-1","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T14:27:56Z","timestamp":1549031276000},"page":"303-306","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Banxia Xiexin Decoction (\u534a\u590f\u6cfb\u5fc3\u6c64) Combined with Afatinib in Treatment of Advanced Gallbladder Cancer: Case Report and Literature Review"],"prefix":"10.1007","volume":"25","author":[{"given":"Li","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao-miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-zhen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-dong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"3152_CR1","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.3748\/wjg.v23.i22.3978","volume":"23","author":"A Sharma","year":"2017","unstructured":"Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update. World J Gastroenterol 2017;23:3978\u20133998.","journal-title":"World J Gastroenterol"},{"key":"3152_CR2","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 2014;6:99\u2013109.","journal-title":"Clin Epidemiol"},{"key":"3152_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-017-3353-2","volume":"80","author":"BJ Kim","year":"2017","unstructured":"Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, et al. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol 2017;80:209\u2013215.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3152_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrclinonc.2014.171","volume":"11","author":"JW Neal","year":"2014","unstructured":"Neal JW, Sledge GW. Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours. Nat Rev Clin Oncol 2014;11:627\u2013638.","journal-title":"Nat Rev Clin Oncol"},{"key":"3152_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13063-015-0685-2","volume":"16","author":"XB Yang","year":"2015","unstructured":"Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, et al. Fuzheng Kang\u2019ai Decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Trials 2015;16:146\u2013152.","journal-title":"Trials"},{"key":"3152_CR6","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.2147\/OTT.S145613","volume":"10","author":"M Ichiki","year":"2017","unstructured":"Ichiki M, Wataya H, Yamada K, Tsuruta N, Takeoka H, Okayama Y, et al. Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinibinduced diarrhea and skin rash in patients with non-small cell lung cancer. Onco Targets Ther 2017;10:5107\u20135113.","journal-title":"Onco Targets Ther"},{"key":"3152_CR7","first-page":"581","volume":"42","author":"O Yamaguchi","year":"2015","unstructured":"Yamaguchi O, Kawashima A, Shiono A, Maeno Y, Ishikawa R, Masumoto A, et al. Hange-Shashin-to for preventing diarrhea during afatinib therapy. Cancer Chemother (Jpn) 2015;42:581\u2013593.","journal-title":"Cancer Chemother (Jpn)"},{"key":"3152_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cdtm.2017.01.003","volume":"3","author":"HX Shen","year":"2017","unstructured":"Shen HX, Song HW, Xu XJ, et al. Clinical epidemiological survey of gallbladder carcinoma in northwestern China, 2009-2013: 2379 cases in 17 centers. Chronic Dis Transl Med 2017;3:60\u201366.","journal-title":"Chronic Dis Transl Med"},{"key":"3152_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12029-012-9369-2","volume":"43","author":"A Romiti","year":"2012","unstructured":"Romiti A, D\u2019Antonio C, Zullo A, Di Rocco R, Barucca V, Durante V, et al. Chemotherapy for the biliary tract cancers: moving toward improved survival time. J Gastrointest Cancer 2012;43:396\u2013404.","journal-title":"J Gastrointest Cancer"},{"key":"3152_CR10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/j.1440-1746.2011.07048.x","volume":"27","author":"U Dutta","year":"2012","unstructured":"Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol 2012;27:642\u2013653.","journal-title":"J Gastroenterol Hepatol"},{"key":"3152_CR11","doi-asserted-by":"crossref","first-page":"58007","DOI":"10.18632\/oncotarget.11157","volume":"7","author":"AR Nam","year":"2016","unstructured":"Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, et al. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget 2016;7:58007\u201358021.","journal-title":"Oncotarget"},{"key":"3152_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/ajco.12592","volume":"13","author":"K Park","year":"2017","unstructured":"Park K, Kim KP, Park S, Chang HM. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. Asia Pac J Clin Oncol 2017;13:13\u201320.","journal-title":"Asia Pac J Clin Oncol"},{"key":"3152_CR13","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1200\/JCO.2012.42.3061","volume":"30","author":"LY Law","year":"2012","unstructured":"Law LY. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J Clin Oncol 2012;30:e271\u2013e283.","journal-title":"J Clin Oncol"},{"key":"3152_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/CCO.0b013e3283620fd8","volume":"25","author":"MG McNamara","year":"2013","unstructured":"McNamara MG, Metran-Nascente C, Knox JJ. State-of-theart in the management of locally advanced and metastatic gallbladder cancer. Curr Opin Oncol 2013;25:425\u2013431.","journal-title":"Curr Opin Oncol"},{"key":"3152_CR15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3030","volume":"46","author":"M Li","year":"2014","unstructured":"Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 2014;46:872\u2013886.","journal-title":"Nat Genet"},{"key":"3152_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/jpet.112.197756","volume":"343","author":"F Solca","year":"2012","unstructured":"Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342\u2013350.","journal-title":"J Pharmacol Exp Ther"},{"key":"3152_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2174\/1568026615666150813144003","volume":"16","author":"L Li","year":"2016","unstructured":"Li L, Zhang L, Yang CC. Multi-target strategy and experimental studies of traditional Chinese medicine for Alzheimer\u2019s disease therapy. Curr Top Med Chem 2016;16:537\u2013548.","journal-title":"Curr Top Med Chem"},{"key":"3152_CR18","first-page":"153473541880153","volume-title":"Integr Cancer Ther 19","author":"H Lu","year":"2018","unstructured":"Lu H, Qin J, Han N, Xie F, Gong L, Li C. Banxia Xiexin Decoction is effective to prevent and control irinotecan-induced delayed diarrhea in recurrent small cell lung cancer. Integr Cancer Ther 19 2018:1534735418801532."},{"key":"3152_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s11655-017-2922-x","volume":"24","author":"HR Kim","year":"2018","unstructured":"Kim HR, Lee GS, Kim MS, Ryu DG, So HS, Moon HC, et al. Effects of Banxia Xiexin Decoction on cisplatin-induced apoptosis of human A549 lung cancer cells. Chin J Integr Med 2018;24:436\u2013441.","journal-title":"Chin J Integr Med"},{"key":"3152_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jep.2015.03.027","volume":"166","author":"G Chen","year":"2015","unstructured":"Chen G, Yang Y, Liu M, Teng Z, Ye J, Xu Y, et al. Banxia xiexin decoction protects against dextran sulfate sodium-induced chronic ulcerative colitis in mice. J Ethnopharmacol 2015;166:149\u2013156.","journal-title":"J Ethnopharmacol"},{"key":"3152_CR21","first-page":"611","volume":"38","author":"J Xiao","year":"2013","unstructured":"Xiao J, Zhang YF, Wang Y, An R, Wang XH. Study on effect of different compatibility of saponins contained in Banxia Xiexin Decoction on intestinal bacterium metabolism. China J Chin Mater Med (Chin) 2013;38:611\u2013617.","journal-title":"China J Chin Mater Med (Chin)"}],"container-title":["Chinese Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11655-019-3152-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-019-3152-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-019-3152-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T02:58:28Z","timestamp":1606359508000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11655-019-3152-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["3152"],"URL":"https:\/\/doi.org\/10.1007\/s11655-019-3152-1","relation":{},"ISSN":["1672-0415","1993-0402"],"issn-type":[{"value":"1672-0415","type":"print"},{"value":"1993-0402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]},"assertion":[{"value":"2 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}